Results 111 to 120 of about 89,184 (204)

Early On‐Treatment Change in SALT as a Pragmatic Predictor of Ritlecitinib Response in Moderate‐To‐Severe Alopecia Areata: A Real‐World Cohort Study

open access: yesInternational Journal of Dermatology, EarlyView.
Ritlecitinib induced rapid clinical improvement in moderate‐to‐severe alopecia areata in real‐world practice. Early change in SALT at Week 12 strongly discriminated Week‐24 responders, supporting a pragmatic treat‐to‐target checkpoint, alongside improvements in clinician‐reported and patient‐reported outcomes and a favorable safety profile.
Giuseppe Gallo   +4 more
wiley   +1 more source

Safety, tolerability, and immunogenicity of a DNA-based vaccine (INO-4700) against Middle East respiratory syndrome coronavirus: phase 2a study in healthy volunteers. [PDF]

open access: yesFront Immunol
Agnes JT   +17 more
europepmc   +1 more source

Bridging the implementation gap in MCABC inventory management: from a taxonomy to practical archetypes

open access: yesInternational Transactions in Operational Research, EarlyView.
Abstract Despite increasing demands for resilient and sustainable supply chains, inventory management often relies on outdated single‐criterion analyses. While multi‐criteria ABC (MCABC) analyses provide a theoretically mature assessment of resilience‐sustainability‐benefit trade‐offs in inventory, their adoption remains limited due to fragmented ...
Lukas Grützner, Michael H. Breitner
wiley   +1 more source

Genetic basis of Asian diabetes

open access: yesJournal of Diabetes Investigation, EarlyView.
ABSTRACT Recent genomic studies in Asian populations have advanced our understanding of the diagnosis, pathophysiology, risk prediction, and precision care of diabetes. Monogenic diabetes, including maturity‐onset diabetes of the young (MODY) and mitochondrial diabetes, highlights the importance of genetic diagnosis for subtype‐specific care.
Takafumi Ojima, Toshimasa Yamauchi
wiley   +1 more source

Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In adults with moderate AD post‐TCS and ‐TCI, who may otherwise be eligible for systemic therapy, 1.5% ruxolitinib cream improved clinical signs and symptoms in the TRuE‐AD4 study. Abstract Background In patients with moderate atopic dermatitis (AD), topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) often do not sufficiently ...
José Manuel Carrascosa   +14 more
wiley   +1 more source

Molecular diagnosis and phylogenetic analysis of a Middle East respiratory syndrome coronavirus human case in Jordan. [PDF]

open access: yesEur J Public Health
Abu-Basha EA   +17 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy